N
Nadia Tornieporth
Researcher at GlaxoSmithKline
Publications - 41
Citations - 9152
Nadia Tornieporth is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: RTS,S & Malaria vaccine. The author has an hindex of 29, co-authored 40 publications receiving 8629 citations. Previous affiliations of Nadia Tornieporth include Sanofi S.A. & Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis
Guillermo M. Ruiz-Palacios,Irene Pérez-Schael,F. Raúl Velázquez,Hector Abate,Thomas Breuer,Sue Ann Costa Clemens,Brigitte Cheuvart,Felix Espinoza,Paul Gillard,Bruce L. Innis,Yolanda Cervantes,Alexandre da Costa Linhares,Pio Lopez,Mercedes Macias-Parra,Eduardo Ortega-Barria,Vesta Richardson,Doris Maribel Rivera-Medina,Luis Rivera,Belén Salinas,Noris Pavía-Ruz,Jorge Salmerón,Ricardo Rüttimann,Juan Carlos Tinoco,Pilar Rubio,Ernesto Nuñez,M. Lourdes Guerrero,Juan Pablo Yarzabal,Silvia Damaso,Nadia Tornieporth,Xavier Sáez-Llorens,Rodrigo Vergara,Timo Vesikari,Alain Bouckenooghe,Ralf Clemens,Beatrice De Vos,Miguel O'Ryan +35 more
TL;DR: Two oral doses of the live attenuated G1P[8] HRV vaccine were highly efficacious in protecting infants against severe rotavirus gastroenteritis, significantly reduced the rate of severe gastroenteropathy from any cause, and were not associated with an increased risk of intussusception.
Journal ArticleDOI
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
Maria Rosario Capeding,Ngoc Huu Tran,Sri Rezeki Hadinegoro,Hussain Imam Muhammad Ismail,Tawee Chotpitayasunondh,Mary Noreen Chua,Chan Quang Luong,Kusnandi Rusmil,Dewa Nyoman Wirawan,Revathy Nallusamy,Punnee Pitisuttithum,Usa Thisyakorn,In-Kyu Yoon,Diane van der Vliet,Edith Langevin,Thelma Laot,Yanee Hutagalung,Carina Frago,Mark Boaz,T. Anh Wartel,Nadia Tornieporth,Melanie Saville,Alain Bouckenooghe +22 more
TL;DR: The findings show that dengue vaccine is efficacious when given as three injections at months 0, 6, and 12 to children aged 2-14 years in endemic areas in Asia, and has a good safety profile.
Journal ArticleDOI
Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
Luis Angel Villar,Gustavo H. Dayan,José Luis Arredondo-García,Doris Maribel Rivera,Rivaldo Venâncio da Cunha,Carmen Deseda,Humberto Reynales,Maria Selma N. Costa,Javier O Morales-Ramirez,Gabriel Carrasquilla,Luis Carlos Rey,Reynaldo Dietze,Kleber Giovanni Luz,Enrique Rivas,Maria Consuelo Miranda Montoya,Margarita Cortés Supelano,Betzana Zambrano,Edith Langevin,Mark Boaz,Nadia Tornieporth,Melanie Saville,Fernando Noriega +21 more
TL;DR: The CYD-TDV dengue vaccine was efficacious against V CD and severe VCD and led to fewer hospitalizations for VCD in five Latin American countries where d Dengue is endemic.
Journal ArticleDOI
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
Arunee Sabchareon,Derek Wallace,Chukiat Sirivichayakul,Kriengsak Limkittikul,Pornthep Chanthavanich,Saravudh Suvannadabba,Vithaya Jiwariyavej,Wut Dulyachai,Krisana Pengsaa,T. Anh Wartel,Annick Moureau,Melanie Saville,Alain Bouckenooghe,Simonetta Viviani,Nadia Tornieporth,Jean Lang +15 more
TL;DR: These data show for the first time that a safe vaccine against dengue is possible, and Dengue vaccine was well tolerated, with no safety signals after 2 years of follow-up after the first dose.
Journal ArticleDOI
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial
Pedro L. Alonso,Jahit Sacarlal,John J. Aponte,Amanda J. Leach,Eusebio Macete,Jessica Milman,Inacio Mandomando,Bart Spiessens,Caterina Guinovart,Mateu Espasa,Quique Bassat,Pedro Aide,Opokua Ofori-Anyinam,Margarita M. Navia,Sabine Corachan,Marc Ceuppens,Marie-Claude Dubois,Marie-Ange Demoitié,Filip Dubovsky,Clara Menendez,Nadia Tornieporth,W. Ripley Ballou,Ricardo Thompson,Joe Cohen +23 more
TL;DR: The results show development of an effective vaccine against malaria is feasible and the RTS,S/AS02A vaccine was safe, well tolerated, and immunogenic.